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We present a series of 26 patients, all 150 years of age, who are carriers of the fragile X premutation and are
affected by a multisystem, progressive neurological disorder. The two main clinical features of this new syndrome
are cerebellar ataxia and/or intention tremor, which were chosen as clinical inclusion criteria for this series. Other
documented symptoms were short-term memory loss, executive function deficits, cognitive decline, parkinsonism,
peripheral neuropathy, lower limb proximal muscle weakness, and autonomic dysfunction. Symmetrical regions of
increased T2 signal intensity in the middle cerebellar peduncles and adjacent cerebellar white matter are thought
to be highly sensitive for this neurologic condition, and their presence is the radiological inclusion criterion for this
series. Molecular findings include elevated mRNA and low-normal or mildly decreased levels of fragile X mental
retardation 1 protein. The clinical presentation of these patients, coupled with a specific lesion visible on magnetic
resonance imaging and with neuropathological findings, affords a more complete delineation of this fragile X
premutation–associated tremor/ataxia syndrome and distinguishes it from other movement disorders.
Introduction
Fragile X syndrome (MIM 309550) is the most common
inherited form of mental retardation. The disorder is
caused by an expansion 1200 repeats (full mutation) of
a trinucleotide element, (CGG)n, located in the 5
′ UTR
of the fragile X mental retardation 1 (FMR1) gene (Ver-
kerk et al. 1991). Full mutation expansions are gen-
erally accompanied by complete or partial silencing
of the FMR1 gene, with subsequent deficiency or ab-
sence of FMR1 protein (FMRP), which leads to fragile
X syndrome.
In contrast, carriers of premutations (55–200 CGG
repeats) typically have normal intelligence, although
emotional difficulties and subtle physical features occur
in ∼25% of these carriers (Dorn et al. 1994; Franke et
al. 1996, 1998; Sobesky et al. 1996; Riddle et al. 1998).
The frequency of the premutation in the general pop-
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ulation is ∼1 in 259 females and 1 in 813 males (Rous-
seau et al. 1995; Dombrowski et al. 2002). A clinical
finding unique to women with the premutation is pre-
mature ovarian failure, which is present in ∼20% of
women who carry premutation expansions (Schwartz
et al. 1994; Allingham-Hawkins 1999).
We recently reported a unique form of clinical in-
volvement in five male carriers of the fragile X pre-
mutation (Hagerman et al. 2001). These men, all 150
years of age, developed progressive intention tremor and
cerebellar ataxia. Their symptoms were accompanied
by progressive cognitive and behavioral difficulties, in-
cluding memory loss, executive function deficits, anxi-
ety, and reclusive behavior. Significant dementia has
been seen in a limited number of patients (Hagerman
et al. 2001; Greco et al. 2002). In addition, more var-
iable features include parkinsonism, peripheral neurop-
athy, lower limb proximal muscle weakness, and au-
tonomic dysfunction (urinary and bowel incontinence
and impotence).
We have also described a hyperintensity on the T2
weighted magnetic resonance (MR) images in the cer-
ebellar white matter and the middle cerebellar peduncles
(MCP) (Brunberg et al. 2002). This remarkable radi-
ological finding, visible in nearly all the premutation
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carriers affected with tremor/ataxia, is not seen in
control individuals. It serves as a major diagnostic
criterion for the fragile X–associated tremor/ataxia syn-
drome (FXTAS).
In five affected individuals examined to date, neu-
ropathological examination has revealed eosinophilic,
intranuclear inclusions in neurons and astrocytes (Greco
et al. 2002; Hagerman et al. 2002). These inclusions
are found throughout the cortex and brain stem, with
the greatest density in the hippocampus and the frontal
cortical regions. Purkinje cells did not possess the in-
clusions, although there was evidence of axonal degen-
eration in the cerebellum (Greco et al. 2002; Hagerman
et al. 2002). These inclusions are polyglutamine nega-
tive, which makes them distinctly different from those
found in the CAG repeat disorders. Results of immu-
nostaining for tau and synuclein were also negative.
For the present report, we have analyzed clinical, ra-
diological, and molecular data on 20 new patients who
met our inclusion criteria (both clinical and radiological;
radiological features previously described by Brunberg
et al. [2002] in 7 patients) and on an additional 6
patients who met the clinical but not the radiological
criteria. This is the only large series published to date.
The consistent clinical presentation of these patients,
associated with a specific lesion visible on MR images
and with neuropathological findings, may distinguish
FXTAS from other movement disorders. We propose
provisional diagnostic criteria to help clinicians recog-
nize this new entity. We also discuss several elements
regarding the progression of the disorder. The presence
of elevated FMR1 mRNA in all patients suggests that
this syndrome may represent a gain-of-function effect
from the elevated message levels (Hagerman et al. 2001;
Greco et al. 2002) as proposed previously for myotonic
dystrophy (Mankodi et al. 2000).
Methods
Ascertainment and Inclusion Criteria
To obtain a homogeneous representation of this neu-
rological disorder in the current series, all patients were
carriers of the premutation and were selected on the basis
of presentation with at least one clinical criterion (ataxic
gait or intention tremor) and one radiological criterion
(presence of symmetric white matter lesions in theMCPs).
Thirty-five men were recruited, either through families
with children affected by fragile X syndrome or through
referring physicians. These patients all presented with late
onset (150 years of age) of neurological symptoms (spe-
cifically, ataxia affecting ambulation and/or tremor)
Twenty of these individuals met the inclusion criteria for
the main series. The remaining 15 men were excluded
from the main series because they did not meet the ra-
diological criteria ( ), did not have results of mag-np 1
netic resonance imaging (MRI) available ( ), or didnp 5
not meet the clinical criteria on examination ( ). Sixnp 9
of the excluded patients who did not meet radiological
criteria are described separately.
Patients were usually examined at one of three sites:
University of Colorado Health Sciences Center ( ),np 4
University of California, Davis, Medical Center (np
), and Rush-Presbyterian–St. Luke’s Medical Center4
( ). Patients not seen in those centers were evalu-np 2
ated on videotape (made during home visits [ 3] ornp
during examination at other neurology departments
[ ]). Of the 20 men in the main series, 4 were de-np 7
ceased; 2 of these 4 men were examined and followed
before death, and 2 were studied retrospectively, with
the use of complete medical records and MRI films.
The clinical examination focused on movement disor-
ders. A videotaped neurological examination was per-
formed in 15 of the 20 patients, using three standardized
scales—the Clinical Rating Scale for Tremors (CRST)
(Fahn et al. 1998), the motor section of the Unified Par-
kinson’s Disease Rating Scale (UPDRS) (Fahn et al.
1987), and the International Cooperative Ataxia Rat-
ing Scale (ICARS) (Trouillas et al. 1997)—to evaluate
tremor, parkinsonism, and cerebellar dysfunction, re-
spectively. The same rating scales were performed on a
group of 20 age-matched male control individuals who
did not carry a premutation FMR1 allele. Male control
subjects were obtained from a population-based epide-
miology study focusing on families with fragile X in the
state of California.
MRI
All 20 patients in the main series underwent an MRI,
which was ordered for clinical purposes in 18/20 patients
and for research purposes in 2/20 patients (performed
under a specific research protocol after obtaining signed
consent). The indications for examination included cer-
ebellar and cognitive symptoms ( ), acute vertigonp 16
( ), multiple-system atrophy (MSA) ( ), andnp 1 np 1
unexplained gait difficulties ( ). All MRIs includednp 2
T1 and T2 weighted images.
Analysis of Genomic DNA and mRNA
Genomic DNA was isolated from peripheral blood
leukocytes, using standard procedures (Puregene; Gen-
tra). Southern blots and PCR analyses were performed
on each sample, as described by Taylor et al. (1994).
For Southern blot analysis, the enzymes EcoRI andNruI
were used for DNA digestion, and StB12.3 was used for
the FMR1-specific probe (Oberle et al. 1991). The
number of CGG repeats was determined using prim-
ers 1 and 3 in the PCR analysis (Brown et al. 1993).
For the analysis of FMR1 mRNA levels, total RNA was
isolated from peripheral blood leukocytes by a single-
step method (Purescript; Gentra). Quantitative (fluores-
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Table 1
Patient Demographics (n p 20)
Characteristic Measure
Mean age  SD (years) 71  6
White 85%
Hispanic 15%
College educated 60%
Grandchild with fragile X syndrome 100%
cence) RT-PCR measurements were performed in 13 pa-
tients, as described by Tassone et al. (2000b).
Immunocytochemical Detection of FMRP
FMRP immunocytochemistry was performed for 13
patients. Blood smears were made from 20 ml of pe-
ripheral blood, following the method described by Wil-
lemsen et al. (1995, 1997). Immunoincubation employed
monoclonal antibodies from hybridoma clone 1C3-1a
(Devys et al. 1993). For each slide, 200 lymphocytes
were counted, and the percent of lymphocytes expressing
detectable FMRP was determined, as described by Tas-
sone et al. (1999).
Results
The 20 men who constitute the inclusion group were all
carriers of premutation (CGG)n expansions (55–200),
with a mean age ( SD) of 71 ( 6) years (table 1).
An additional six men, who had clinical symptoms but
did not satisfy radiological criteria for inclusion, are pre-
sented separately. All patients had a family history of
fragile X syndrome. Before presenting a detailed view of
the clinical, radiological, and molecular data, we will
summarize two case reports that are representative of
the main clinical presentations.
Patient 1 is a 77-year-old left-handed former engineer
with the Air National Guard and the National Aeronau-
tics and Space Administration who carries fragile X pre-
mutation (85 CGG repeats). He first noticed tremor in
his left hand, in his early 40s, as a very transient phe-
nomenon after flying a jet aircraft. At age 60 years, he
noticed worsening of his tremor related to job stress, and
he switched to writing with his right hand. However, in
his mid-60s, the tremor extended to the right hand.
At age 64 years, neurological examination showed
dystonic tremor of the upper extremities, evidenced by
marked intention and postural tremor (without resting
tremor), positional exacerbation of tremor, and dra-
matic improvement of tremor with intravenous sco-
polamine. Toes were up-going bilaterally, and reflexes
were brisk. Throughout his 70s, gait instability became
increasingly prominent. At age 72 years, examination
showed continuing tremor, ataxia in the heel-to-shin
test, loss of vibration sense in the feet, and loss of pin-
prick discrimination below the knees. Deep tendon re-
flexes were absent in the ankles and were 1 in the
knees. The patient also complained of muscle weakness
in his right leg, and muscle testing revealed a deficit in
his hip flexors (3/5 on the right) and quadriceps (4/5
on the right). Electrical studies revealed normal con-
duction, but electromyelographic examination found
evidence of denervation, suggesting an L3-L4 radicu-
lopathy, although the appearance of the spinal cord was
normal on MRI. He wore a knee brace for a year be-
cause his knee gave out frequently. MRIs performed at
ages 68 and 77 years showed generalized atrophy, as
well as a bilateral increased T2 signal intensity in the
MCPs. By age 77 years, atrophy became severe, partic-
ularly in the parietal lobe. Other medical problems in-
cluded diabetes, which was diagnosed at age 76 and
was treated by diet. The patient had no history of ex-
cessive alcohol consumption. At 77 years old, he un-
derwent angioplasty. Recovery from the procedure was
protracted. After anesthesia, 48 h were necessary to re-
gain consciousness and orientation. Two months later,
the patient’s motor function was still not back to base-
line, with marked lower limb proximal weakness. There
was no evidence of stroke or focal neurological anom-
alies, and heart function was normal.
Patient 2 is a 73-year-old premutation carrier (70
CGG repeats), who retired from the U.S. Air Force at
50 years of age. In his mid 40s, he noted fatigue and
aching in his legs. In his early 50s, he started walking
with a cane because of an unstable drunkenlike gait and
numbness and weakness of the legs. At age 62 years,
one knee frequently gave out, precipitating falls.
The patient’s bilateral leg numbness (more pro-
nounced on the left than on the right) has progressed
over the past 20 years, ascending to a point just below
the knees. He also noted a deterioration of fine motor
coordination over the past several years, causing diffi-
culty with writing and manipulating small buttons. A
gradual decline in hearing has been accompanied by
tinnitus. He has had episodic bladder and bowel in-
continence since his early 60s.
Neurological examination at age 73 years revealed
gaze-evoked nystagmus, mild dysarthria, mild muscle
weakness in the arms and weakness in the legs that
was more pronounce proximally than distally. Gait
was very unsteady and wide based. Reflexes were 2
throughout, except for absent ankle jerks. Babinski re-
sponse was flexor. Sense of vibration was minimally
reduced in the feet. DNA testing was negative for he-
reditary neuropathy with liability to pressure palsies
(HNPP) and spinocerebellar atrophy (SCA1, -2, -3, -6,
and -7). Electrical studies (including electromyography
[EMG] and nerve conduction) at age 73 years suggested
a mild distal axonal polyneuropathy or distal motor
neuron process.
Electrical studies at age 76 years showed mild-to-mod-
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Table 2
Clinical Summary
CONDITION
AFFECTED SUBJECTS (%)
Main
Groupa
(n p 20)
Additional
Groupb
(n p 6)
Reported symptom:
Gait difficulties 95 83
Leg weakness 55 55
Leg pain 35 50
Leg numbness 35 33
Deterioration of fine motor skills 90 83
Significant writing impairment 95 83
Clinical findingc:
Cerebellar ataxia:
Dysarthria 78 …
Dysmetria 93 …
Postural and gait abnormalitiesc 86 …
Tremor:
Intention 70 83
Resting alone 10 17
Combined (frequency 3–5 Hz) 30 17
Parkinsonian symptomd:
Mild bradykinesia 57 …
Mild rigidity
Upper extremity 71 …
Lower extremity 35
Cogwheeling 5 …
Neuropathy below the kneee 60 30
Muscle testing:
Proximal lower limb !5 30 …
Distal lower limb !5 10 …
Other medical problems (n p 20):
Urinary incontinence 55 17
Bowel incontinence 30 0
Impotence 80 50
Heart diseasef 55 50
Hypertension 50 50
a Patients meeting both the radiological criteria and at least one
clinical criterion.
b Patients not having MRIs ( ) or not meeting radiologicalnp 5
criteria ( ).np 1
c Patients were required to have a score of at least one on the items
of the ICARS referred to for each symptom. Results were obtained on
14 videotaped patients.
d Patients were required to have a score of at least one on the items
of the UPDRS referred to for each symptom. Results were obtained
on 14 videotaped patients.
e Neuropathy was identified clinically by impaired toe position or
absence of pinprick or vibration sensation.
f History of ischemia related to congestive heart failure.
erate, distal, symmetric, sensory-motor polyneuropathy
with axonal demyelination features. Results of muscle
biopsy were normal. Brain MRI showed a marked in-
crease in T2 signal intensity in the white matter of the
anterior portions of the cerebellar hemispheres, extending
toward and including the MCPs bilaterally. There were
∼30 scattered high signals in the corona radiata. Tremor
was absent during all clinical examinations.
Clinical Findings
The clinical findings for the 20 men who met the in-
clusion criteria and the additional 6 men are summarized
in table 2. The most prominent complaints were directly
related to the inclusion criteria: gait difficulties (95%
of the patients) and impaired fine motor skill (90%
of the patients), with writing impairments in 90% of
the patients (related to tremor in 71%). Other com-
plaints, unrelated to the inclusion criteria, were fluctu-
ating muscle weakness (50%) and numbness and/or pain
(35%) in the lower extremities. Forty-five percent of
the patients could not walk more than one block.
Impotence (82%) and urinary (53%) and bowel (30%)
incontinence were also frequent. In four men, pain was
a major complaint, which required treatment (gabapen-
tin being effective in three patients). Pain was described
as burning or cramping or as paresthesias. In two pa-
tients, it was associated with effort, and arteritis was
excluded by Doppler ultrasonography.
On the clinical examination, four symptoms were pre-
sent in the majority of patients: gait ataxia, intention
tremor, parkinsonism, and lower extremity neuropathy.
We performed logistic regression analyses on the sum-
mary scores of the CRST, ICARS, and UPDRS, com-
paring 15 male carriers with 20 age- and sex-matched
control individuals. Male carriers of the premutation
demonstrated significant impairment on the three stan-
dardized scales which measured tremor (CRST, Pp
), cerebellar dysfunction (ICARS, ), and.006 Pp .004
parkinsonian symptoms (UPDRS, ) (table 3).Pp .001
Cerebellar symptoms.—Such symptoms as postural
and gait disturbance, dysmetria, and dysarthria were
found in 78%–93% of the patients, depending on the
type of symptom (table 2). Dysarthria (ICARS section
15–16), dysmetria (ICARS sections 15 and 16), and gait
and postural symptoms (ICARS sections 1, 2, and 6)
were scored in the mild-to-moderate range of problems.
Tremor.—Tremor was intentional (typically 3–5 Hz) in
70% of patients, including intentional and mild resting
in 30%, and was resting alone in 10%. Tremor was com-
pletely absent in 20% of patients (e.g., patient 2). Inten-
tion tremor always started in the dominant hand and
progressed to the contralateral hand in the following
years. The severity of the intention tremor was always
discordant with the milder cerebellar symptoms (dysme-
tria and postural symptoms). The intention tremor was
most frequently activated by writing. In four patients,
moderate-to-severe impairment of fine motor skill was
present in patients without clinically recognizable tremor.
Lower distal neuropathy.—Neuropathies, such as abol-
ished reflexes, loss of vibration sense, and abnormal pin-
prick discrimination and proprioception response, were
present in 61% of patients. The levels of neuropathy
were below the knee in all patients except one, in whom
the symptoms extended to the thigh. Peripheral electro-
physiological studies were performed in four patients,
and nerve conduction was mildly but clearly reduced in
all four. Thirty-six percent of patients also reported leg
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Table 3
P Values and Odds Ratios Differentiating Male Carriers of FMR1
Premutation (n p 15) from Age- and Sex-Matched Control
Individuals (n p 20) on Three Standardized Neurological Scales
Scale and Item P
Odds
Ratio
ICARS:
Dysarthria fluency of speech .048 .17
Dysmetria, right arm .07 .08
Dysmetria, left arm .010 .05
Intention tremor of finger: .12
Right .013
Left .009 .10
Standing capacitiesa .028 .11
Body sway with feet togethera .019 .12
Walking capacities .001 .02
Gait speed .019 .15
UPDRS:
Facial expression .003 .07
Speech .015 .12
Finger taps, left .016 .13
Leg agility: .006 .08
Right
Left .013 .11
Postural stability .038 .08
Gait .004 .07
CRST:
Speaking .038 .08
Arm intention tremor .022 .17
Handwriting .001 .04
First drawing:b
Right hand .035 .18
Left hand .011 .12
Second drawing:c
Right hand .001 .03
Left hand .060 .22
Third drawing:d
Right hand .002 .06
Left hand .033 .18
a Eyes open.
b Small spiral.
c Large spiral.
d Straight line.
pain. In four patients, lower extremity arteritis was ex-
cluded by Doppler ultrasonography.
Parkinsonism.—Parkinsonian symptoms were present
in 57% of the patients. Mild bradykinesia (UPDRS 31)
was present in 57% of the patients. Rigidity, which was
rated as slight or was detected only when activated by
mirror movements (UPDRS 22), was found in the upper
limbs in 71% of the patients and in the lower limbs in
35%. Rigidity was scored as moderate in only three
patients. The mean score of the UPDRS motor domain
was 34/108. Slight resting tremor was present in 40%
of patients. None of the patients presented with severe
parkinsonian features or typical Parkinson disease.
Clinical muscle testing.—Lower limb muscle weakness
was present in 30% of the patients. Abnormal results
of muscle testing occurred predominantly in the proxi-
mal muscle groups, with some muscle groups (psoas-
gluteus) being as weak as 3/5. Toes were up-going or
equivocal in 23% of the patients. However, there were
no clear pyramidal symptoms, except for one patient
who presented with a positive Babinski reflex and spas-
ticity (initially diagnosed as amyotrophic lateral scle-
rosis). EMG of the lower extremities revealed borderline
spontaneous activity in two patients (in proximal muscle
groups). In the patient with spastic paraparesis, tran-
scranial stimulation showed a significant blockage of
the corticomotor neuron connection. Spine MRIs, per-
formed in six patients, revealed no evidence of com-
pression or radiculopathy. Results of a muscle biopsy
performed on one patient were normal.
Cardiovascular symptoms.—A history of ischemia
and/or congestive heart failure was present in 55% of
patients. Hypertension was present in 50%.
Additional patients.—An additional group of six pa-
tients was not included in the main series because the
MRI was not available ( ) or did not demonstratenp 5
the main neuroimaging inclusion criterion ( ).np 1
These patients had similar clinical presentations (table
2), with similar proportions of gait instability (83%),
leg weakness (55%), intention tremor (83%), and rest-
ing tremor (17%). Urinary (17%) and bowel (0%) in-
continence were less frequent. Results of standardized
rating scales were not obtained for these patients.
Cognitive Symptoms
A relatively consistent pattern of cognitive impairment
was observed among those individuals ( ) whonp 11
underwent a cognitive neuropsychological examination.
Those who had been affected longest had lower IQ
scores on the Wechsler Adult Intelligence Scale–III
(Wechsler 1997). This was noteworthy on the perform-
ance (nonverbal) scales, in which scores ranged from 70
to 114 (mean 89.5). Difficulty on nonverbal tasks re-
flected both the effects of the movement disorder (since
many of the tests involve manipulation of the materials
and timing of performance) and impairment of working
memory. Verbal IQ scores ranged from 77 to 128 (mean
97.3).
Deficits in executive cognitive functioning were es-
pecially noteworthy, and these were consistent with a
behavioral pattern that included disinhibition, distrac-
tibility, and inappropriate jocularity. On the Behavioral
Dyscontrol Scale (BDS) (Grigsby et al. 1998), only 3 of
11 individuals demonstrated a capacity for behavioral
self-regulation that was in the normal range for age.
Similarly, performance on tests of verbal fluency was
significantly impaired, with only 3 of 11 scoring in the
average range on the Animal Naming Test of the Boston
Diagnostic Aphasia Examination (Goodglass and Kap-
lan 1983); 4 of 10 were in the average range on a word-
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Figure 1 Executive function decline correlated to disease du-
ration: linear and quadratic regression.
Figure 2 MRI findings, T2-weighted axial images of the cerebellum. a,Normal T2 weighted axial image of the cerebellum (arrows indicate
cerebellar white matter). b and c, Symmetrical regions of increased T2 signal intensity in the MCPs. d–h, Adjacent cerebellar white matter.
generation test involving phonemic cues (Controlled
Oral Word Association Test [Spreen and Benton 1977]).
Apart from impaired executive functioning, the most
commonly observed cognitive deficits were impairment
in the speed and capacity of information processing.
When compared with a series of 90 control individ-
uals—matched to patients for sex, age, and educa-
tion—who were given the BDS in another study, the
decline of the BDS score with age is significantly greater
in the premutation group (slope of the regression line
for the premutation group, 0.390; slope of the regression
line for the control group, 0.189). Using a linear re-
gression to correlate the increase of mistakes on the BDS
with the duration of the disease, we found a significant
correlation ( , ) (fig. 1).rp 0.736 Pp .004
MRI
The presence of symmetric white matter lesions of the
MCP was a mandatory inclusion criterion for the 20
patients. These lesions were strikingly similar (fig. 2),
demonstrating decreased T1 and increased T2 signal
intensity in deep white matter of the cerebellar hemi-
spheres and the MCPs, sparing the dentate nuclei (fig.
2). Mild-to-moderate loss of cerebellar hemisphere cor-
tical volume was present in 85% of the patients and was
severe in one patient. Mild-to-moderate loss of cerebral
cortical volume was present in 75% of the patients (fig.
3). The volume loss was severe in 20% of the patients.
Areas of increased T2 signal intensity in the subepen-
dymal and deep white matter, disproportionate for age,
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Figure 3 Coronal inversion recovery image demonstrating se-
vere parietal volume loss and increased signal intensity in the cerebellar
white matter.
Table 4
Molecular Findings
Mean  SD
CGG repeat number 84  10
FMR1 RNA levelsa 4  2
FMRP levels (%) 75  8
a RNA levels are reported as fold elevated
over those in normal control individuals.
were present in the frontal and parietal lobe in 75% of
the patients. Three patients demonstrated more-diffuse
white matter T2 hyperintensities, extending from the
periventricular areas to the entire adjacent white mat-
ter. In two patients, the neuroradiologists diagnosed
Binswanger disease, on the basis of the great extent of
white matter disease on T2 andMRIs of fluid-attenuated
inversion recovery.
Progression Of Clinical Involvement
Patients experienced onset of intention tremor at a
mean ( SD) age of 63 ( 8) years, gait instability at
63 ( 6) years, memory difficulties at 63 ( 6) years,
urinary incontinence at 64 ( 6) years. Half (55%) of
our patients required a cane, beginning at a mean age of
70 ( 7) years; 35% of the patients required a walker
at 71 ( 6) years; 30% of the patients required a wheel
chair at 72 ( 5) years. The onset of the first ambulation
impairment (use of a cane) was not significantly correlated
( ) with the onset of the disorder. Three patientsPp .174
were bedridden at ages 55, 65, and 80 years. Additional
data from five deceased patients previously reported by
us (Hagerman et al. 2001; Greco et al. 2002) were also
added. The mean ( SD) age at death was 74 ( 6)
years. In 9 patients, the age at death was correlated with
the age at onset of the disorder ( ). The cause ofPp .039
death was reported as congestive heart failure in 8/9 pa-
tients and as pneumonia in 1/9 patients.
Molecular Findings
Molecular findings are summarized in table 4. Our
patients were all in a very narrow CGG count range
(mean 84; range 69–99). The FMRP levels (mean [
SD] 75% [ 8]) were borderline or slightly lower than
those reported in nonaffected premutation carriers (Tas-
sone et al. 1999;Willemsen et al. 1997), and two patients
revealed levels just below 70%. Correlations between
CGG repeat count, mRNA levels, FMRP levels, and age
at disease onset were not statistically significant.
Discussion
The patients were selected to obtain a conservative rep-
resentation of FXTAS. They were required to meet one
clinical criterion (intention tremor or ataxia) in addition
to a specific radiological criterion (symmetric white mat-
ter lesions of the MCP) to be included in this series. This
group of patients allows us to delineate FXTAS and to
describe the progression and the frequency of other
symptoms that are not among the inclusion criteria. We
have also presented clinical data on six additional pa-
tients who met the clinical, but not the radiological cri-
terion. For the latter group, the clinical presentations
were similar to those of the inclusion group.
Elsewhere, we described a cerebellar white matter le-
sion involving the MCP and deep cerebellar white mat-
ter (fig. 2), and we demonstrated its association with
the neurological findings (Brunberg et al., 2002). This
MCP finding is the most specific marker of FXTAS,
other than the neuropathologic feature of intranuclear
inclusions (Greco et al. 2002). We have not found these
radiological signs in six asymptomatic male carriers of
the premutation (150 years old) (authors’ unpublished
data), suggesting that the MRI findings are closely re-
lated to the clinical manifestations. However, two pa-
tients have presented with moderate parkinsonism, and
one patient has a combination of intention tremor and
cerebellar ataxia, in the absence of MCP lesions (un-
published data), so the association is not absolute. Re-
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Table 5
Symptom Types
Examination and Degree Observation
Radiological:
Major MRI white matter lesions in MCPs and or brain stem
Minor MRI white matter lesions in cerebral white matter
Minor Moderate-to-severe generalized atrophy
Clinical:
Major Intention tremor
Major Gait ataxia
Minor Parkinsonism
Minor Moderate-to-severe short-term memory deficiency
Minor Executive function deficit
NOTE.—Inclusion criterion: CGG repeat 55–200.
cently, the MCP lesion has been described in as many
as 42% of a group of patients with MSA type C (Bhat-
tacharya et al. 2002; Naka et al. 2002).
In the early stage of the disorder, patients may present
with only one clinical symptom (essential tremor being
the most common), which can suggest many diagnoses
(Leehey et al. 2003). The breadth of early clinical di-
agnoses is suggestive of great clinical heterogeneity;
however, as the disorder progresses, these patients gen-
erally develop gait ataxia, intention tremor, parkinson-
ism, peripheral neuropathy, and cognitive decline. In
our group, 55% of the patients combined three of these
symptoms. Thus, in the later stages of the disorder, the
clinical and radiological picture can resemble multiple-
system atrophy–cerebellar type (MSA-C).
Four factors appear to play a role in the walking
difficulties: cerebellar ataxia, peripheral neuropathy,
parkinsonian symptoms, and lower extremity muscle
weakness. The cerebellar symptoms appear to be re-
sponsible for part of the instability and abnormal gait
reported by the patients. Parkinsonian symptoms are
mild and do not appear to contribute to the loss of
ambulation (posture, postural stability, gait, and bra-
dykinesia were scored in the mild range on the UPDRS
for the majority of patients). Impaired proprioception
is also common and could contribute to instability.
In the course of disease progression, precipitating fac-
tors seem to play an important role. Four of our patients
experienced dramatic clinical decline after medical pro-
cedures that required general anesthesia. In two of these
patients, computed axial tomography excluded strokes.
None of the four patients ever returned to baseline levels
of cognitive and motor function. The duration of the
anesthesia seemed to correlate with the extent of the
motor and cognitive declines. The significant correlation
( ) of the age at death and at onset of the dis-Pp .039
order in a small sample ( ) suggests that FXTASnp 9
is a significant factor in the death of these patients.
Congestive heart failure was reported as the cause of
death in 8/9 patients, suggesting that FXTAS is a risk
factor for heart failure. This finding needs to be con-
firmed in a larger sample with age-matched controls. It
should be noted that our sample is probably biased with
regard to the progression and severity of disease, be-
cause many of these patients were reported to us as a
result of the severity of their clinical presentation.
To aid in the diagnosis of FXTAS, we propose three
diagnostic categories: “definite,” “probable,” and “pos-
sible.” Each category reflects combinations of symptom
types (see table table 5 for definitions of symptom
types). The diagnostic categories are as follows:
1. “Definite” indicates the presence of one major ra-
diological sign plus one major clinical symptom.
2. “Probable” indicates the presence of either one ma-
jor radiology sign plus one minor clinical symptom or
two major clinical symptoms.
3. “Possible” indicates the presence of one minor ra-
diology sign plus one major clinical symptom.
The criteria for definite diagnosis were used for the
20 patients of the main series in the present article. The
six additional patients, who did not meet the radiolog-
ical criterion, fell into the categories of probable diag-
nosis ( ) or possible diagnosis ( ). In this se-np 4 np 2
ries, the CGG repeat number is in the mid-to-low
premutation range, and the sample could be biased by
the fact that all of the included individuals have a grand-
child affected with fragile X. We do not know the limits
of repeat size responsible for this disorder; it is likely
that as we identify patients who attend neurology clinics
and do not have a family history of fragile X, we will
see lower numbers of CGG repeats. Furthermore, the
range of CGG repeats (55–200) defining the premuta-
tion could be different from the range of CGG repeats
responsible for this new disorder, which may start at
!54 and end at 1200 (135 repeats being the highest
repeat observed to date [Greco et al. 2002]). Further
studies and different means of ascertainment are needed
to determine the lower and upper limits of the CGG
repeat associated with this disorder, and further clini-
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copathological/radiological correlates will help refine
the diagnostic criteria for this syndrome.
As presently defined, FXTAS appears to be limited to
older adult male carriers of the premutation. This strik-
ing sex ratio bias is consistent with an X-linked disorder.
However, we do not know why the bias is so much
greater than for fragile X syndrome. The progressive
neurological phenotype associatedwith the premutation
allele places the FMR1 gene in the same category as
most of the other trinucleotide repeat disorders, includ-
ing those with gain of function (e.g., CAG repeats in
SCA1, -2, -3, -6, and -7; Huntington disease; spino-
bulbar-muscular atrophy; and dentatorubropallidoluy-
sian atrophy) or a loss of function (e.g., SCA8 or -12
or Friedreich ataxia).
Only 40% of the patients had a positive family history
in first- or second-degree relatives for Parkinson disease,
dementia, or unspecified progressive neurological disor-
ders. Therefore, the penetrance of this disorder among
male premutation carrierswill be incomplete and, inmost
of the families, will manifest itself as a sporadic condition.
We are currently conducting an epidemiological study in
California, which suggests that the penetrance is age re-
lated (authors’ unpublished data).
Conclusion
We now believe that the FMR1 gene is responsible for
two distinct clinical entities: a neurodevelopmental dis-
order (fragile X syndrome) and a neurodegenerative dis-
order (FXTAS). The full expansion (1200 CGG repeats)
is responsible for the silencing of the FMR1 gene through
methylation (Pieretti et al. 1991). In fragile X syndrome,
the lack of FMRP causes mental retardation and other
behavioral symptoms. However, in the patients de-
scribed herein, there is no evidence for a neurodevel-
opmental disorder in childhood; 60% of the patients had
a college education, and FMRP levels were normal or
only mildly decreased. We suggest that this disorder is
allelic to the fragile X syndrome and should be consid-
ered as a distinct neurodegenerative disorder. The mo-
lecular mechanism leading to FXTAS is likely to be quite
distinct from the silencing mechanism operating in frag-
ile X syndrome and, as suggested previously (Hagerman
et al. 2001; Greco et al. 2002), may be related to a gain-
of-function toxic effect of the elevated FMR1 mRNA
levels (and, specifically, elevated CGG repeat levels) pre-
viously reported (Tassone et al. 2000a, 2000b;Kenneson
et al. 2001). The mechanism of an mRNA gain of func-
tion has been proposed for myotonic dystrophy, on the
basis of the demonstration, in transgenic mice, that the
myotonia phenotype was obtained by expressing un-
translated CUG repeats alone (Mankodi et al. 2000).
Finally, we suggest that DNA testing for the FMR1 pre-
mutation may reveal additional carriers among patients
presenting clinically with MSA, essential tremor asso-
ciated with late-onset cerebellar ataxia, or atypical Par-
kinson disease.
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